News & Events
Conference 2022 Event Schedule
Please join KOVA International and Biochemical Diagnostics at the following conferences this year. We will be showcasing our latest offerings and technologies and will have our top product experts on hand to answer your questions! Contact us to set up individual appointments at any of the following events.
AACC (American Association For Clinical Chemistry)
JULY 24-28, 2022, CHICAGO IL
SOFT (Society of Forensic Toxicologists) Annual Meeting
OCTOBER 30-NOV 4, 2022
HUNTINGTON CONVENTION CENTER, CLEVELAND, OHIO
NDASA (National Drug and Alcohol Screening Association)
MAY 4-6, 2022, INDIANAPOLIS, IN
DATIA (Drug and Alcohol Testing Industry Association)
MARCH 30-APRIL 2, 2022, LOUISVILLE, KENTUCKY
RE: DEVICE REGISTRATION UPDATE:
Effective April 18th 2022, Biochemical Diagnostics has transitioned our EU Representative from Emergo to ADVENA LIMITED.
The following product lines are affected:
DETECTABUSE LIQUID CONTROL URINE
PREGNANCY-SKREEN hCG LIQUID CONTROL
SALIVABUSE LIQUID CONTROL ORAL FLUID
All products previously shipped for sale in any CE Countries are valid under the previous authorized representative and no action needs to be taken.
New orders placed with us after May 5th, will updated labeling to reflect our new Authorized Representative:
ADVENA LIMITED, Tower Business Centre, 2nd Floor, Tower Street, Swatar BKR, 4013 Malta
Please contact us if you have any questions or concerns.
KOVA INTERNATIONAL INC. ACQUIRES BIOCHEMICAL DIAGNOSTICS, INC.
Posted on : June 06, 2016
GARDEN GROVE, CA, JUNE 3, 2016 – Kova International, Inc. (“Kova”) announced today that it has acquired Biochemical Diagnostics, Inc. (“Biochemical Diagnostics”). The transaction was completed on April 22, 2016. Financial terms of the transaction were not disclosed. Founded in 1981, Biochemical Diagnostics, based in Edgewood, NY is a leading manufacturer and marketer of controls and disposable sample preparation products used in drugs of abuse testing. Biochemical Diagnostics’ products are utilized in toxicology and clinical laboratories and also in handheld devices for point of care testing. The acquisition of Biochemical Diagnostics expands Kova’s product line into the drugs of abuse testing area and provides the combined company with opportunities to cross-sell Biochemical Diagnostics’ products through Kova’s robust distribution network.
“This acquisition builds on Kova International’s 35 years of innovation and quality, supporting our strategic priorities and further expanding Kova’s product offerings and value proposition. Biochemical Diagnostics enhances the KOVA brand through its FDA/DEA approved products, recognized brand name and ISO certified manufacturing practices. Kova increases Biochemical Diagnostics’ distribution reach and diversifies its product portfolio,” said Nita Moritz, President of Kova.
Allen Panetz, the founder of Biochemical Diagnostics, who will remain with the company following the transaction, commented, “The entire Biochemical Diagnostics team is excited to be joining the Kova family knowing that the expansion of the company’s footprint to two locations, one on the East Coast and one on the West Coast will be of immense benefit to our combined customers. Kova’s resources will enable us to expand the reach of our product offering and develop new products while continuing to provide high quality controls and a robust line of sample preparation disposables and equipment to our loyal customers.”